Our study has confirmed that although this variation is certainly present, Ki67 nevertheless has strong prognostic value for breast cancer mortality in women with ER-positive, HER2-negative early IBC in the general hospital setting, even after adjusting for a wide range of patient and tumor factors. This evidence concerns the gene ERBB2 and breast cancer.